BRIEF-Novartis Says Data From Eclipse Trial "Really Doesn't Change" Plans For Cosentyx [Reuters]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Reuters
BRIEF-Novartis Says Data From Eclipse Trial Really Doesn't Change Plans For Cosentyx | Reuters 1 Min Read Dec 12 (Reuters) - Novartis AG: * WE BELIEVE DATA FROM ECLIPSE TRIAL, WHICH TESTED NOVARTIS’ COSENTYX AGAINST JNJ’S TREMFYA , WILL HAVE LIMITED CLINICAL RELEVANCE - NOVARTIS EXECUTIVE SAYS ON CONF. CALL * DATA FROM ECLIPSE TRIAL, WHICH TESTED NOVARTIS’ COSENTYX AGAINST JNJ’S TREMFYA, REALLY DOESN’T CHANGE OUR PLANS - NOVARTIS EXECUTIVE SAYS ON CONF. CALL Further company coverage: All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays. © 2018 Reuters. All Rights Reserved. BRIEF-Novartis Says Data From Eclipse Trial "Really Doesn't Change" Plans For Cosentyx Dec 12 (Reuters) - Novartis AG: * WE BELIEVE DATA FROM ECLIPSE TRIAL, WHICH TESTED NOVARTIS’ COSENTYX AGAINST JNJ’S TREMFYA , WILL HAVE LIMITED CLINICAL RELEVANCE - NOVARTIS EXECUTIVE SAYS ON CONF. CALL * DATA FROM ECLIPSE TRIAL, WHICH TESTED NOVARTIS’ COSENTYX AGAINST JNJ’S TRE
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN) [Yahoo! Finance]Yahoo! Finance
- New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)PR Newswire
- Food Allergy Pipeline Landscape Research Report 2024: Comprehensive Insights About 30+ Companies and 35+ Pipeline Drugs [Yahoo! Finance]Yahoo! Finance
- Bayer's patent for blood thinner Xarelto invalid, UK court rules [Reuters]Reuters
- Penicillin Intermediates Market Size to Grow USD 14330 Million by 2029 at a CAGR of 5.2% | Valuates Reports [Yahoo! Finance]Yahoo! Finance
NVS
Earnings
- 1/31/24 - Miss
NVS
Sec Filings
- 2/15/24 - Form S-8
- 2/2/24 - Form SC
- 1/31/24 - Form 6-K
- NVS's page on the SEC website